

Correction: Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study

Takashi Iizuka^a, Kotaro Iemitsu^a, Masahiro Takihata^a, Masahiko Takai^a, Shigeru Nakajima^a, Nobuaki Minami^a, Shinichi Umezawa^a, Akira Kanamori^a, Hiroshi Takeda^a, Takehiro Kawata^a, Shogo Ito^a, Taisuke Kikuchi^a, Hikaru Amemiya^a, Mizuki Kaneshiro^a, Atsuko Mokubo^a, Tetsuo Takuma^a, Hideo Machimura^a, Keiji Tanaka^a, Taro Asakura^a, Akira Kubota^a, Sachio Aoyagi^a, Kazuhiko Hoshino^a, Masashi Ishikawa^a, Yoko Matsuzawa^a, Mitsuo Obana^a, Nobuo Sasai^a, Hideaki Kaneshige^a, Fuyuki Minagawa^a, Tatsuya Saito^a, Kazuaki Shinoda^a, Masaaki Miyakawa^a, Yasushi Tanaka^{a, b}, Yasuo Terauchi^c, Ikuro Matsuba^{a, d}

Corrections to article “Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study”, by Takashi Iizuka et al, published in Vol. 8, No. 2, 2016, p116-125, doi: <http://dx.doi.org/10.14740/jocmr2417w>.

There were some errors in Table 2, the authors would like to make the following corrections.

The baseline postprandial blood glucose level (mg/dL) should read 199.1 ± 85.2 , instead of 199.1 ± 1.49 .

The 12 weeks postprandial blood glucose level (mg/dL) should read 154.9 ± 60.5 , instead of 54.9 ± 60.5 .

Manuscript accepted for publication January 20, 2016

^aStudy Group of the Diabetes Committee, Kanagawa Physicians Association, Kanagawa, Japan

^bDivision of Metabolism and Endocrinology, Department of Internal Medicine, St. Marianna University School of Medicine, Kanagawa, Japan

^cDepartment of Endocrinology and Diabetes, Yokohama City University Medical Center, Kanagawa, Japan

^dCorresponding Author: Ikuro Matsuba, Matsuba Medical Clinic, 2-159 Tsukagoshi, Saiwai-ku, Kawasaki-shi, Kanagawa 212-0024, Japan.

Email: ikuro@matsuba-web.com

doi: <http://dx.doi.org/10.14740/jocmr2417wc1>